Analyst Consensus ?
ConsensusBuy29 ratings
Bullish1551.7%
Neutral1448.3%
Bearish00.0%
Revvity, Inc. · RVTY · FY2026 Q3 · Calendar Q4 2026
Revvity Raises FY2026 Outlook After 7% Q3 Organic Growth
Q3's stronger organic growth and another full-year guidance increase support an improving operating trajectory. The outlook still depends on sustaining demand, converting instrument backlog, and how much bulk reagent ordering and AI-related activity persist into Q4.
Reported Before market openNYSEHealthcare
$16.92B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.30
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $694.7M
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+10.8%
Event window
SPY move
+0.4%
Same window
Abnormal move
+10.4%
Stock minus SPY
Volume
1.0×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
RVTYSPY benchmark
Ask FN2 about RVTY FY2026 Q3
Transcript, numbers and history already loaded
What drove RVTY's +10.8% move after FY2026 Q3 earnings?What changed in RVTY's guidance and outlook in FY2026 Q3?Give me the bull and bear case for RVTY after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with Q2, reported organic growth accelerated from 3% to 7%, and management raised its full-year outlook again: organic growth to 5% and adjusted EPS to $5.40–$5.45. The Q3 analysis attributes growth to Life Sciences and Diagnostics performance, with acquisition contribution and expanding AI-related demand also cited.
Guidance delta
Management raised FY2026 organic-growth guidance to 5% and adjusted-EPS guidance to $5.40–$5.45, following the prior quarter's 4–5% organic-growth and $5.30–$5.40 adjusted-EPS outlook.
Key takeaways
- Q3 organic revenue growth was 7%, with Life Sciences and Diagnostics identified as important contributors.
- The company raised full-year organic-growth and adjusted-EPS guidance.
- Management described AI-related demand as broadening beyond high-content screening, while analysts pressed for clarity on its revenue contribution.
- New Signals software offerings and the certified T1D assay expand the product pipeline; ACD/Labs is an additional contributor.
- The Q4 outlook warrants attention to bulk-order timing and the conversion of instrument backlog.
Management priorities
- Scale capacity for high-content screening and other instrument lines.
- Continue extending the Signals software suite, including AI-related products.
- Advance the T1D assay pipeline, including the broader assay collaboration with Sanofi.
- Integrate ACD/Labs and progress the China immunodiagnostics divestiture.
Follow RVTY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$167.77Current
$95Low
$124.13Average
$165High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Oct 13, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Oct 7, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Sep 4, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 5, 2026 |
| Stifel | Hold | Hold | Maintain | May 6, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 6, 2026 |
| Baird | Outperform | Outperform | Maintain | May 4, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Apr 14, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 3, 2026 |
| Jefferies | Hold | Hold | Maintain | Feb 3, 2026 |
| B of A Securities | Buy | Buy | Maintain | Sep 22, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Jul 29, 2025 |
| UBS | Buy | Neutral | Upgrade | May 1, 2025 |
| Bernstein | Outperform | Outperform | Maintain | Nov 5, 2024 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 17, 2024 |
| Citigroup | Buy | Buy | Maintain | Jul 30, 2024 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Dec 5, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Nov 13, 2022 |
| Needham | Buy | Buy | Maintain | Nov 8, 2020 |
| CFRA | Hold | Hold | Maintain | May 5, 2020 |
| Piper Sandler | Neutral | Overweight | Downgrade | Oct 30, 2019 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jan 2, 2019 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Nov 1, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 8, 2018 |
| Mizuho | Neutral | Buy | Downgrade | Aug 4, 2016 |
| Wedbush | Neutral | Outperform | Downgrade | Dec 2, 2015 |
| ISI Group | Neutral | Buy | Downgrade | Apr 8, 2014 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 9, 2013 |
| CLSA | Buy | Outperform | Maintain | Jan 16, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $167.77. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $160 | $153.3 | -4.6% | Oct 7, 2026 |
| UBS | Analyst unavailable | $140 | $127.08 | -16.6% | Sep 9, 2026 |
| KeyBanc | Analyst unavailable | $165 | $130.63 | -1.7% | Sep 4, 2026 |
| RBC Capital | Dan Leonard | $135 | $128.67 | -19.5% | Sep 1, 2026 |
| Evercore ISI | Vijay Kumar | $125 | $111.66 | -25.5% | Jul 6, 2026 |
| Bernstein | Analyst unavailable | $115 | $113.53 | -31.5% | Jun 26, 2026 |
| Stifel Nicolaus | Analyst unavailable | $100 | $92.3 | -40.4% | May 6, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $117 | $92.3 | -30.3% | May 6, 2026 |
| Robert W. Baird | Analyst unavailable | $125 | $86.68 | -25.5% | May 4, 2026 |
| Barclays | Luke Sergott | $95 | $92.64 | -43.4% | Apr 14, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $129 | $103.89 | -23.1% | Feb 3, 2026 |
| Cowen & Co. | Analyst unavailable | $124 | $106.97 | -26.1% | Feb 3, 2026 |
| Evercore ISI | Analyst unavailable | $118 | $107.09 | -29.7% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $118 | $107.09 | -29.7% | Feb 3, 2026 |
| Jefferies | Analyst unavailable | $105 | $107.05 | -37.4% | Feb 2, 2026 |
| Wells Fargo | Brandon Couillard | $107 | $100.46 | -36.2% | Dec 15, 2025 |
| Barclays | Luke Sergott | $115 | $100.46 | -31.5% | Dec 15, 2025 |
| Goldman Sachs | Evie Koslosky | $105 | $99.79 | -37.4% | Dec 9, 2025 |
| Robert W. Baird | Analyst unavailable | $123 | $97.74 | -26.7% | Oct 28, 2025 |
| Barclays | Analyst unavailable | $105 | $97.16 | -37.4% | Oct 28, 2025 |
| Evercore ISI | Analyst unavailable | $108 | $95.88 | -35.6% | Oct 27, 2025 |
| Robert W. Baird | Catherine Ramsey Schulte | $122 | $98.64 | -27.3% | Oct 24, 2025 |
| Barclays | Analyst unavailable | $100 | $91.76 | -40.4% | Oct 2, 2025 |
| Raymond James | Andrew Cooper | $140 | $116.6 | -16.6% | Jan 21, 2025 |
| Bernstein | Eve Burstein | $130 | $113.88 | -22.5% | Jan 10, 2025 |
| KeyBanc | Paul Knight | $132 | $124.82 | -21.3% | Nov 4, 2024 |
| Barclays | Luke Sergott | $140 | $122.91 | -16.6% | Oct 15, 2024 |
| Bank of America Securities | Derik de Bruin | $127 | $125.59 | -24.3% | Jul 30, 2024 |
| Jefferies | Tycho Peterson | $125 | $125.29 | -25.5% | Jul 29, 2024 |
| Stifel Nicolaus | Daniel Arias | $110 | $120.16 | -34.4% | Jul 29, 2024 |
| Citigroup | Patrick Donnelly | $135 | $120.16 | -19.5% | Jul 29, 2024 |
| Evercore ISI | Vijay Kumar | $126 | $120.16 | -24.9% | Jul 29, 2024 |
| UBS | Dan Leonard | $120 | $105.02 | -28.5% | Apr 29, 2024 |
Track every rating change on RVTY the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationRevvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers.…
Historical context
All RVTY earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FMS Fresenius Medical Care AG & Co. KGaA | FY2026 Q3 · Calendar Q4 2026 | — | -3.6% | Fresenius Medical Care cuts 2026 outlook as cost and reimbursement pressure persist |
| WAT Waters Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +3.8% | Waters Raises FY2026 Revenue Outlook as Organic Growth Accelerates |
| HSIC Henry Schein, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +0.0% | Henry Schein raises 2026 EPS outlook as U.S. dental sales grow |
| PHG Koninklijke Philips N.V. | FY2026 Q3 · Calendar Q4 2026 | — | +4.8% | Philips Q3: order momentum and margins improve; outlook held |
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
Latest beats and misses
Who reports nextBeat on EPS
- EQH-PAFY2026 Q3 · November 2, 2026+14.5% EPS— move
- WMBFY2026 Q3 · November 2, 2026+0.2% EPS+3.5% move
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
Missed on EPS
- CRBGFY2026 Q3 · November 2, 2026-0.8% EPS+2.5% move
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
Get the RVTY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-03T16:05:19.745731+00:00
- FN2 earnings calendar · 2026-11-03T01:23:13.143323+00:00
- Polygon adjusted daily market bars · 2026-11-03T18:00:47.586056+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T18:00:47.583311+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.